image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Tristel - Well placed to prosper from MRSA problem

November 2005

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • TSTL
  • Price:
  • 47p
Tristel, a tiddler (market cap. £11.2m) which was introduced to AIM by Teather & Greenwood on 1 June at 37p, looks like a company that could easily be in the right place at the right time. The company has developed a range of products for disinfecting medical instruments and with lack of hospital cleanliness being blamed for the spread of anti-biotic resistant superbugs, it seems well-placed to benefit from the expected wall of money that the government is likely to throw at this problem.  Tristel, which uses a proprietary technology to destroy all types of bacteria (including tuberculosis and MRSA), fungi and viruses, has quickly grown to become one of the market leaders in its niche, supplying 60% of all hospitals ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMTED TIME OFFER

SUBSCRIBE TODAY AND SAVE £30 USING OFFER CODE 30OFFTMI

To access our archive of articles and receive current issues you need to subscribe